ArticleClinical cancer research : an official journal of the American Association for Cancer Research2022

Phase I Trial Combining Chemokine-Targeting with Loco-Regional Chemoimmunotherapy for Recurrent, Platinum-Sensitive Ovarian Cancer Shows Induction of CXCR3 Ligands and Markers of Type 1 Immunity.

Brian Orr et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.